Prostate cancer is the most common spite among older adults. Many studies prove that treatment of metastatic cancer with hormone therapy temporarily controls symptoms by 70%-80%. The progressive metastatic hormone-refractory disease remains a therapeutic challenge. However, therapeutic approaches can be tumoricidal to hormone-refractory cancerous cells and improve the quality of life without causing adverse effects. Extensive research
The post IMMUNOTHERAPY FOR PROSTATE CANCER WITH VDTP/GC-MAF appeared first on Healing Oracle.